Brief: Zelluna: Phase II Dovacc Trial Of UVI Cancer Vaccine Does Not Meet Primary Endpoint
26/06/2026 15:42
BRIEF-Zelluna: Phase II Dovacc Trial Of UVI Cancer Vaccine Does Not Meet Primary Endpoint June 26 (Reuters) - Zelluna ASA ZLNA.OL:
PHASE II DOVACC TRIAL OF UV1 CANCER VACCINE DOES NOT MEET PRIMARY ENDPOINT
CONSIDERS UV1 CANCER VACCINE PROGRAMME CLOSED
DOES NOT EXPECT FURTHER MATERIAL COSTS RELATED TO UV1 PROGRAMME
Source text: ID:nGNE8BrFJJ
Further company coverage: ZLNA.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant